AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03071354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB protein supplement (3g)
Description: HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
Study NCT03071354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement
Description: Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
Study NCT01500200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Two active tablets, given daily
Study NCT01500200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets, given daily
Study NCT03502369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Quadratus lamborum block
Description: Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
Study NCT00621673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kogenate (BAY 14-2222)
Description: Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
Study NCT03098550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT01740193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
Study NCT01740193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal/iliohypogastric blockade
Description: Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
Study NCT02310568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Study NCT02310568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06372865.
Description: Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
Study NCT02966028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNF472
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Study NCT04201457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib capsule; Dabrafenib Dispersible Tablet
Study NCT04201457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Tablet; Powder for Oral Solution
Study NCT04201457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tablet
Study NCT04519619 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT01224613 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: 0.1 mL of Intanza intradermally at visit # 1
Study NCT01303718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioFit® System
Description: Vagal nerve stimulation with the CardioFit® system
Study NCT01303718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Usual care for LV dysfunction and heart failure (no CardioFit System implant)
Study NCT01183520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil provided by salmon
Description: Eating 3 different amounts of provided salmon twice a week for four weeks
Study NCT00201422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Clarithromycin
Description: Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
Study NCT04838054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stabilized chlorine dioxide oral rinse
Description: Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
Study NCT04838054 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received a rinse containing no active ingredients and periodontal basic therapy.
Study NCT04150146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg after high-fat meal
Description: Test Drug
Study NCT04150146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rebamipide SR 150mg under fasting condition
Description: Reference Drug
Study NCT04494542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Low Efficiency Dialysis (SLED)
Description: sustained low efficiency dialysis (SLED)
Study NCT04494542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Renal Replacement Therapy
Description: Continuous Renal Replacement Therapy
Study NCT02193737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early oral fluid recovery.
Study NCT02193737 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed oral fluid recovery.
Study NCT02957747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE
Description: SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
Study NCT01228136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
Study NCT01228136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline solution
Description: normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
Study NCT04660851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coached
Description: 10-weeks of diet coaching weekly by telephone to improve dietary protein intake
Study NCT03590626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
Study NCT04098419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science for Life
Description: The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
Study NCT03294044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICT programs
Description: ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
Study NCT03294044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A book about chronic disease
Description: A Take-home book about chronic disease are provided for self-education
Study NCT01242839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CACICOL20
Description: CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
Study NCT01242839 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
Study NCT00321074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACROLIMUS
Description: Immunosuppression
Study NCT00321074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: Immunosuppression
Study NCT03632993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum (CCH)
Description: Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
Study NCT02184091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT03515135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Executive Function Training
Description: Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
Study NCT02966028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
Study NCT03764566 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
Study NCT01224613 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: 0.1 mL of Intanza intradermally at visit #1
Study NCT00569387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HyperAcute(R)-Pancreatic Cancer Vaccine
Description: 100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
Study NCT02629224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral
Study NCT02574611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT02574611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Study NCT02574611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (Placebo)
Study NCT02574611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Colonic Manometry
Study NCT02574611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Resolution Colonic Manometry
Study NCT02574611 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High Resolution Colonic Manometry
Study NCT03872063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
Study NCT03872063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
Study NCT02043041 — intervention group
Intervention type: OTHER
Intervention: Number of DBS Spots
Description: The number of DBS spots on the card constitutes the experimental condition.
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Ezetimibe 10 mg tablet
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atorvastatin 10 mg capsule
Study NCT02550288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin 10 mg capsule
Study NCT02550288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
Study NCT02550288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet control/Daily Exercise
Description: Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
Study NCT02384473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-Time CEUS
Description: Undergo real-time CEUS
Study NCT02384473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWE
Description: Undergo SWE
Study NCT02384473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Suspension for Injection
Description: Participant will receive contrast agent by intravenous administration
Study NCT02384473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Shear Wave Elastography
Description: Type of equipment used for SWE
Study NCT04548934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal protective equipment (PPE)
Description: Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
Study NCT04548934 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Personal protective equipment (PPE)
Description: Standard CPR without wearing PPE
Study NCT00606034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 Insulin delivered by Omnipod (disposable insulin pump)
Description: U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
Study NCT01243372 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT01243372 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT03037359 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bivigam
Description: Human immune globulin
Study NCT03037359 — intervention group
Intervention type: BIOLOGICAL
Intervention: Other
Description: Human immune globulin
Study NCT03116802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril (live attenuated yellow fever vaccine)
Description: They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
Study NCT03116802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stamaril (live attenuated yellow fever vaccine)
Description: They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
Study NCT02078180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: generic bupropion
Description: We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
Study NCT02995161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
Study NCT02995161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT03122678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Study NCT03122678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03525301 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions
Study NCT03525301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 1800 cGy in 4 fractions administered twice a day
Study NCT00332020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
Study NCT00332020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg enoxaparin syringe administered for 12 +/- 2 days
Study NCT04571424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB133 (Dapirolizumab pegol)
Description: Administered as specified in the treatment arm
Study NCT04571424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT02503670 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychoeducational modules to prevent/reduce depression
Description: Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
Study NCT02503670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Continue with standard care.
Study NCT01413906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923 (XL139)
Description: Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
Study NCT02543177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography
Study NCT02543177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic precondition
Description: four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
Study NCT01905800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.